Selective PARP1 inhibitor(Acerand Therapeutics)

Oral presentation to highlight safety and preliminary efficacy of EIK1001 in combination with pembrolizumab Separate poster presentations will highlight EIK1001 both in combination with pembrolizumab and chemotherapy (trial in progress) and safety and preliminary efficacy in combination with atezolizumab A Phase 1 study of the PARP1-selective inhibitor, EIK1003, will be highlighted in a poster presentation (trial in progress) HAYWARD, Calif.--(BUSINESS WIRE)--Eikon Therapeutics, Inc., a pioneering biotechnology company that leverages advanced engineering to enhance drug discovery and development, announced today that multiple abstracts highlighting its clinical-stage TLR 7/8 co-agonist (EIK1001) and PARP1-selective inhibitor (EIK1003) programs will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago May 31 – June 4, 2024. The oral presentation (Abstract: 2521) highlights safety and preliminary efficacy data from a clinical study (NCT03486301) of EIK1001, a Toll-like receptor 7/8 (TLR7/8) co-agonist, in combination with pembrolizumab in participants with advanced solid tumors. The new data show that EIK1001 was well-tolerated with a manageable safety profile, and showed encouraging preliminary efficacy across several tumor types in combination with pembrolizumab. Responses were observed even in heavily pretreated patients not anticipated to respond to pembrolizumab monotherapy. Anthony W. Tolcher, MD, FASCO, of New Experimental Therapeutics (NEXT), will deliver the presentation on June 2, 2024 at 12:42 PM CDT. “We are encouraged by the promising data emerging from our lead clinical programs,” said Roy D. Baynes, MB.BCh., Ph.D., Chief Medical Officer of Eikon Therapeutics. “The safety and preliminary efficacy results for EIK1001, in combination with pembrolizumab and with atezolizumab, underscore the potential of these promising approaches. We highlight also the advancement of EIK1001 into front-line combinations with standard-of-care pembrolizumab and chemotherapy in non-small cell lung cancer, and of our PARP1-selective inhibitor, EIK1003, into phase 1 studies in cancers selected for specific genotypes.” In addition, three posters will be presented and include: Title: A first-in-human (FIH), phase 1/2, dose-escalation, dose-optimization, and dose-expansion study of PARP1-selective inhibitor EIK1003 (IMP1734) in participants with advanced solid tumors. Abstract Number: TPS3191 (Poster Bd# 320b) Abstract Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology Date/Time: June 1, 2024, 9:00 AM – 12:00 PM CDT Presenter: Guru Sonpavde, MD, Medical Director of Genitourinary Oncology, Assistant Director of the Clinical Research Unit and Christopher K. Glanz Chair for Bladder Cancer Research, AdventHealth Cancer Institute. Title: Safety and preliminary efficacy of EIK1001 in combination with atezolizumab in participants with advanced solid tumors. Abstract Number: 2618 (Poster Bd# 97) Abstract Session: Developmental Therapeutics—Immunotherapy Date/Time: June 1, 2024, 9:00 AM – 12:00 PM CDT Presenter: Manish Patel, MD, Director of Drug Development, Florida Cancer Specialists & Research Institute/Sarah Cannon Research Institute. Title: A phase 2 study of EIK1001, a Toll-like receptor 7/8 (TLR7/8) agonist, in combination with pembrolizumab and chemotherapy in patients with stage 4 non-small cell lung cancer. Abstract Number: TPS8667 (Poster Bd# 521b) Abstract Session: Lung Cancer—Non-Small Cell Metastatic Date/Time: June 3, 2024, 1:30 PM – 4:30 PM CDT Presenter: Dan Costin, MD, FACP, Director, White Plains Hospital, Center for Cancer Care. Eikon will also host a booth in the exhibition hall (#32116) at the 2024 ASCO Annual Meeting. About Eikon Therapeutics Eikon Therapeutics seeks to advance breakthrough therapeutics through the purposeful integration of engineering and science. Our proprietary discovery technologies leverage Nobel Prize-winning super-resolution microscopy, advanced engineering, and high-performance computing to visualize and measure the real-time movement of proteins in living cells, with the goal of bringing important new medicines to people suffering from grievous illness. Eikon operates from its facilities in California, New Jersey, and New York and can be found online at or LinkedIn.

SHANGHAI and WARREN, N.J., April 7, 2024 /PRNewswire/ -- Laekna (2105.HK) announced that the company has presented two internally-discovered preclinical candidates, in addition to a poster presentation on a clinical trial, at the 2024 Annual Meeting of the American Association for Cancer Research (AACR) in San Diego, California. The presentations featured preclinical data of two novel selective inhibitors, LAE119, a novel PARP1 selective inhibitor and trapper, and LAE120, a novel selective USP1 inhibitor. "After advancing LAE102, our internally discovered antibody against ActRIIA, into IND stage, Laekna continues to strengthen our internal discovery efforts, with new drug candidates emerging", said Dr. Justin Gu, Chief Scientific Officer of Laekna. "The MOA of LAE119 and LAE120 is synthetic lethality, both exhibit strong anti-tumor efficacy and good safety in preclinical models. LAE 119 is a PARP1-selective inhibitor with the strongest DNA-trapping activity among all the PARP inhibitors tested. It shows good activity even in tumor cells with low PARP1 protein level. LAE120 is a novel USP1 inhibitor currently at IND-enabling studies stage. It has a unique chemical scaffold differentiated from all the other disclosed USP1 inhibitors and is expected to induce a different conformational change in USP1. The quick advance of these two projects into PCC stage demonstrates the effectiveness of the close collaboration among Med Chem, Biology and AIDD (AI-driven Drug Discovery) teams. Laekna will continue our internal effort of discovery novel drug candidates to provide more options for patients." Laekna's internal discovery focuses on innovation, scarcity, and differentiation, covering three areas: cancer, metabolic diseases，and liver fibrosis. The company has internally discovered 14 drug candidates, among which seven have been optimized and advanced to PCC (pre-clinical candidate) stage. The company plans to have one drug candidate entering the clinical stage each year. The Annual Meeting of AACR is set for April 05 to 10, 2024 at the San Diego Convention Center, California, USA. It is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. [1] Presentation details are as follows: Title: Preclinical characterization of LAE119, a novel PARP1 selective inhibitor and trapper Authors: Ming Li, Yan Chen, Junyan Chen, Ling Jiang, Xiaofen Lin, Justin Gu Session Category: Experimental and Molecular Therapeutics Session Title: DNA Damage and Repair Session Date and Time: Wednesday, Apr 10, 2024 9:00 AM- 12:30 PM (PT) Location: Poster Section 22 Poster Board Number: 27 Abstract Highlights: LAE119 is a potent and selective PARP1 inhibitor and PARP1-DNA trapper. It demonstrates more than 1000-fold selectivity for PARP1 DNA trapping activity over PARP2. In comparison to most PARP inhibitors including AZD5305, LAE119 exhibits extremely long residence time on PARP1 in both biochemical and cellular assays and shows good activity even in tumor cells with low PARP1 protein level. It demonstrates robust anti-tumor effect in BRCA2-/- DLD-1 and MDA-MB-436 Xenograft models and has minimal effects on hematologic parameters. Full texts of the abstracts are available here. Title: Preclinical candidate LAE120, a novel selective USP1 inhibitor shows effective anticancer and combination activity with PARP inhibitors Authors: Jintao Wang, Yan Chen, Junyan Chen, Ling Jiang, Xiaofen Lin, Chaojun Cai, Minhua Zhang, Ming Li, Justin Gu Session Category: Experimental and Molecular Therapeutics Session Title: Novel Antitumor Agents 2 Session Date and Time: Sunday, Apr 7, 2024 1:30 PM- 5:00 PM (PT) Location: Poster Section 27 Poster Board Number: 16 Abstract Highlights: LAE120 is a novel, allosteric and highly potent USP1 inhibitor, displaying monotherapy potency and combination activity with PARP inhibitor in HRD (homologous recombination deficiency) cancers. It has a unique chemical structure differentiated from all the other disclosed USP1 inhibitors and is expected to induce a different conformational change in USP1. LAE120 shows robust tumor inhibitory activity in MDA-MB-436 and K562 xenograft models as a single agent and exhibits synergistic effect in combination with PARP inhibitors. LAE120 demonstrates good therapeutic window in DRF study and is currently at IND-enabling stage. Full texts of the abstracts are available here. About Laekna Founded in 2016, Laekna is a science-driven, clinical-stage biotechnology company committed to bringing novel therapies to cancer, metabolic diseases and liver fibrosis patients worldwide. As of December 31, 2023, we have initiated six clinical trials for Afuresertib (LAE002), LAE001 and LAE005 for the treatment of breast cancer, prostate cancer, ovarian cancer and PD-1/ PD-L1 drug-resistant solid tumors to address the unmet medical needs. Among the six clinical trials, three are multi-regional clinical trials (MRCTs). Afuresertib is a potent AKT inhibitor that inhibits all three AKT isoforms (AKT1, AKT2 and AKT3) as well as one of the only two AKT inhibitors in or completed the pivotal-stage clinical development for anti-cancer treatment globally. Laekna's internal drug discovery platform has discovered 14 drug candidates. LAE102 is our internally discovered antibody against ActRIIA. We've submitted IND applications to CDE and FDA respectively for LAE102 in relation to obesity in the first quarter of 2024. Blocking Activin-ActRII pathway could promote skeletal muscle regeneration and decrease fat mass. Laekna team has accumulated tremendous experiences and deep knowhow in this specific field and is developing more drug candidates (LAE103 and LAE123) to maximize the value of targeting ActRII receptors. Laekna, Inc. was listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "Hong Kong Stock Exchange") on June 29, 2023, with the stock code 2105.HK. For more information, please visit: or Forward Looking Statements This press release may contain certain "forward-looking statements" which are not historical facts, but instead are predictions about future events based on Laekna's current beliefs, assumptions, and expectations, commonly identified by words such as "would", "may", "expects", "believes", "plans", "intends", "projects" and other terms with similar meaning. Although we believe that our predictions are reasonable, future events are inherently uncertain and our actual future results or performance may be materially different from what we expect. Accordingly, you are strongly cautioned that reliance on any forward-looking statements is subject to significant known and unknown risks and uncertainties. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section. All information provided in this press release is as of the date of this press release and are based on assumptions that we believe to be reasonable as of this date, and we do not undertake any obligation to update any forward-looking statement, except as required under applicable law. SOURCE Laekna